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Abstract: Significant amounts of enolase—a cytosolic enzyme involved in the glycolysis pathway—are
exposed on the cell surface of Candida yeast. It has been hypothesized that this exposed enolase
form contributes to infection-related phenomena such as fungal adhesion to human tissues, and the
activation of fibrinolysis and extracellular matrix degradation. The aim of the present study was
to characterize, in structural terms, the protein-protein interactions underlying these moonlighting
functions of enolase. The tight binding of human vitronectin, fibronectin and plasminogen by
purified C. albicans and C. tropicalis enolases was quantitatively analyzed by surface plasmon
resonance measurements, and the dissociation constants of the formed complexes were determined
to be in the 10−7–10−8 M range. In contrast, the binding of human proteins by the S. cerevisiae
enzyme was much weaker. The chemical cross-linking method was used to map the sites
on enolase molecules that come into direct contact with human proteins. An internal motif
235DKAGYKGKVGIAMDVASSEFYKDGK259 in C. albicans enolase was suggested to contribute
to the binding of all three human proteins tested. Models for these interactions were developed and
revealed the sites on the enolase molecule that bind human proteins, extensively overlap for these
ligands, and are well-separated from the catalytic activity center.
Keywords: non-albicans Candida species; enolase; moonlighting protein; vitronectin;
fibronectin; plasminogen
1. Introduction
Enolase (2-phospho-D-glycerate hydrolase, EC 4.2.1.11) catalyzes the interconversion between
2-phosphoglycerate and phosphoenolpyruvate that occurs during the glycolysis (forward reaction) and
gluconeogenesis (reverse reaction) pathways. Aside from this fundamental and evolutionally conserved
function however, enolase is highly multifunctional (for reviews see: [1–3]). Since the first reports of
“gene sharing” by enolase and τ-crystallin—a structural protein of the eye lens [4,5], numerous further
studies have assigned enolase a status of one of the best characterized of the “moonlighting
proteins”—single polypeptide chains that perform two or more fundamentally different and unrelated
functions which are not due to gene fusion, alternative mRNA splicing, proteolytic generation of
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different protein variants or promiscuous enzyme activity [6]. These additional functions occur
via a priori unexpected interactions with non-canonical molecular targets and sometimes at an
“unauthorized” subcellular or extracellular location that is not consistent with the classical rules of
protein sorting [7]. Enolase is primarily an intracellular (cytosolic) protein. In Escherichia coli cells,
it moonlights as a component of the RNA degradosome [8,9]. In Saccharomyces cerevisiae yeast it
serves as a heat shock protein, Hsp48 [10], and, in a complex with some other glycolytic enzymes,
sticks to the outer mitochondrial membrane, thereby mediating the transport of aminoacyl-tRNAs to
the mitochondrial matrix to facilitate intra-mitochondrial protein synthesis [11,12]. In the cytosol of
mammalian cells enolase contributes to the regulation of cell morphology via interactions with tubulin
and microtubules [13], binds cholesterol esters thus decreasing the cellular cholesterol level [14,15],
and acts as a hypoxic stress protein, HAP47 [16,17]. Albeit lacking typical signal peptides, enolase also
appears in the nucleus where it functions as a c-myc promoter-binding protein (MCB-1) to regulate
the transcription of the c-myc proto-oncogene [18,19], and on various human cell surfaces where
it can act as an autoantigen [20], or a receptor for plasminogen where it modulates pericellular
fibrinolytic activity [1], with further pathophysiological consequences. Notably, enolase and an array
of other moonlighting proteins are exposed on the surface of pathogenic bacteria and some eukaryotic
pathogens, and contribute to their virulence, primarily via adherence to the host cells and proteins,
or through interference with host immune mechanisms (for reviews see: [7,21–24]).
Recent proteomic studies have repeatedly demonstrated the presence of enolase at the cell
surface of yeast-like fungi from the Candida genus [25–28], a major group of fungal pathogens
in humans. Commensally inhabiting the skin and mucosal membranes of healthy individuals,
these fungi can cause severe infections in hospitalized patients with impaired immune mechanisms [29].
Although Candida albicans is still the main fungal species isolated from the bloodstream, the incidence
of infections caused by species other than C. albicans, which are an increasingly emerging cause of
systemic and poorly curable candidiases, has been growing in recent decades [30,31]. One of these
other pathogenic species is C. tropicalis, which is currently considered to be the second or third causative
agent of fungal diseases, depending on geographical location, accounting for almost 31% of infections
in Asia, 17% in the USA, and 15–21% in Latin America [32]. In several prior studies, malignancies,
mainly in the hematopoietic system, were indicated as the dominant factor increasing the risk of
infection with this species [33,34].
Several lines of evidence have clearly confirmed an important role of enolase in candidal virulence.
For example, enolase was reported as the predominant antigen detected during C. albicans-dependent
infections [35]. Moreover, a C. albicans enolase-null mutant, although capable of surviving and
growing in media with a non-fermentable carbon source, exhibited increased susceptibility to certain
antifungal drugs, was defective in hypha formation, and was avirulent in mice [36]. Owing to an
additional transglutaminase activity, enolase takes part in the maintenance of cell wall integrity, in the
morphological transition of fungi, and in the protection against osmotic stress [37]. This enzyme
was also shown to be an important factor in the process of fungal adhesion to biomaterials such as
polyvinylchloride and silicone, which are commonly used in medical devices including catheters,
valves or orthopedic prostheses [38]. Like in other pathogenic microbes, multiple moonlighting proteins
that are present on candidal cell surfaces have been primarily anticipated to contribute to the adhesion
of the pathogen to the host tissues. This phenomenon is critical for the colonization and infection of
the host, and these proteins, loosely associated with the fungal cell wall, probably act collectively [7].
They therefore complement the basic role of the major dedicated adhesins that are covalently anchored
to the cell wall and are surface-displayed in a tightly controlled fashion in a response to signals from the
host environment [39]. Many studies have pointed to enolase as a main moonlighting adhesin at the
candidal cell surface [40–42], although the relative contribution of this protein to the entire phenomenon
of candidal adhesion to the host can vary depending on the infection stage and context. In some
reports, the role of enolase in fungus-host adhesion was suggested to be critical. A prior study reported
the suppressive effects of anti-enolase antibodies and recombinant enolase on C. albicans adhesion to
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intestinal mucosa, which was found to decrease by 48–70% [40]. Proteins reported to be targets for
candidal enolase in the human host have included the cadherins on epithelial and endothelial cells [40],
to which the fungal pathogen adheres at the initial stages of host colonization [43], and during the
later dissemination of the pathogen within the host organism [36,44], respectively. Additional target
proteins include those of the basal membrane such as laminin (LAM), and extracellular matrix (ECM)
components such as fibronectin (FN) or vitronectin (VTR) [45]. These structures become exposed after
damage to the tight protective cell layers, thus providing additional points for pathogen attachment.
Another area in which the interactions of candidal moonlighting proteins, including enolase,
with host proteins have been confirmed to contribute to fugal pathogenicity is the interference
with the host homeostatic/hemostatic systems based on proteolytic cascades such as the fibrinolysis,
complement and kallikrein-kinin systems (for a review see: [7]). The best studied example is the
binding of human plasminogen (HPG), a phenomenon that has been reported to occur universally
on the surfaces of many types of prokaryotic and eukaryotic cells [1]. Binding of HPG and its
active form, plasmin, to the surface of the yeast allows the pathogen to participate in the process
of clot fibrinolysis, enabling the release of pathogens trapped inside. Furthermore, the proteolytic
activity of plasmin can also activate collagenases and mediators involved in the activation of the
complement system, thereby contributing to the degradation of components of the human ECM [46,47]
and facilitating the penetration of surrounding tissues [48,49]. Enolase is one of multiple HPG-binding
moonlighting proteins found at the cell surface of C. albicans [48,50] and other medically important
Candida species [51].
The current state of knowledge regarding moonlighting proteins in various taxa, including candidal
enolase, does not include an extensive characterization of the structural factors that determine the tight
interactions of these proteins with host proteinaceous targets. Such studies would add considerably to
the discussion on how a priori unexpected moonlighting functions could have arisen during evolution
through the adaptation of previously unused molecule surfaces as new binding sites for diverse ligands,
and also without any changes to previous structural determinants of the main functions of the protein
in question [52]. As long as this alternative function did not disrupt the core enzymatic function,
these multifunctional proteins could have persisted during the course of evolution [23]. It seems that
very small changes in a protein’s covalent structure can change its biological function [53]. These changes
can be unique for a given protein and not necessarily conserved among its homologues [54]. The likely
types of such changes would include, for example, posttranslational modifications, such as those
reported for mammalian enolases [1]. An interesting issue, particularly important for candidal cytosolic
proteins that unexpectedly appear on the cell surface, regards possible structural differences between
these two forms.
Some of these issues are addressed in our present study, in which we aimed to conduct a
structural characterization of the interactions between candidal enolase and the host proteins that
have been repeatedly reported to be potential enolase ligands i.e., VTR, FN and HPG. The cytosolic
and cell wall-associated enolase forms of two candidal species: C. albicans and C. tropicalis were
compared in terms of their human protein-binding profiles. The complexes formed were mapped by
chemical cross-linking and visualized by molecular modelling. For HPG, some reference data on its
binding to enolase from other organisms are available [55–57], but no structural characteristics of ECM
protein-enolase interactions have been reported previously.
2. Results
2.1. Soluble Purified Candidal Enolases and Anti-Enolase Antibodies Inhibit the Adsorption of Human VTR,
FN and HPG to Fungal Cells
We obtained several forms of candidal enolase i.e., purified from the C. albicans cell wall and cytosol,
purified from the C. tropicalis cytosol, and recombinant C. albicans proteins produced in E. coli (both
wild-type and specifically designed mutant forms). The purified proteins were analyzed by sodium
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) (Figure S1 in the Supplementary
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material), unequivocally identified by liquid chromatography-coupled tandem mass spectrometry
(LC-MS/MS), and confirmed to be non-glycosylated via carbohydrate-specific in-gel staining.
The specific enzymatic activities of the purified enolases were comparable (ca. 100 units/mg protein).
First, to test the hypothesis that enolase exposed at the candidal cell surface contributes significantly
to the phenomenon of human protein binding to the whole candidal cell, we analyzed the inhibitory
effects of soluble fungal enolases and anti-enolase antibodies on the adsorption of VTR, FN and HPG
to C. albicans and C. tropicalis hyphae/pseudohyphae (Figure 1). The results indicated that the fungal
cell-binding of human proteins decreased by 20–25% and 30–40%, respectively, in the presence of
competitors. This initial experiment provided a good biological rationale for subsequent structural
analyses of the enolase interactions with the human host proteins under analysis.
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Figure 1. Effects of C. albicans and C. tropicalis purified enolases (A) or anti-enolase antibody (B) on 
the binding of biotin-labeled human proteins―vitronectin (VTR-Bt), fibronectin (FN-Bt), 
plasminogen (HPG-Bt)―to Candida spp. cells. Candida spp. hyphal or pseudohyphal forms, settled 
in the wells of a MaxiSorp microplate (1 × 106 cells per well), were (A) incubated with mixtures of 40 
µL of VTR-Bt, FN-Bt or HPG-Bt (at the final amount of 2 pmoles) with 10 µL of purified Candida spp. 
enolases (final amount of 24 pmoles); or (B) pre-incubated with the fungal anti-enolase antibodies (1 
µg/µL and then treated with 50 µL of VTR-Bt, FN-Bt or HPG-Bt (at a final concentration of 250 nM). 
After washing off unbound protein, the amount of bound human protein was determined using the 
streptavidin-horseradish peroxidase/tetramethylbenzidine SA-HRP/TMB system. Bars represent the 
mean values from three determinations with standard deviations. Statistical significance levels 
against the 100% controls were determined using a one-way ANOVA test: * p < 0.05, ** p < 0.01 and 
*** p < 0.001. 
2.2. The Equivalent Human Protein-Binding Abilities of C. albicans Cell Surface-Exposed and Cytosolic 
Enolases  
Two methods were utilized to compare the binding of the human VTR, FN and HPG proteins 
by both the cell surface-exposed and cytosolic forms of C. albicans enolase. The overall binding levels 
were first semi-quantitatively analyzed using a microplate ligand-binding assay, based on the 
interaction of biotin-labeled enolase with polystyrene-immobilized human protein (Figure S4 in the 
Supplementary material). Second, the advanced method of surface plasmon resonance (SPR) 
measurements was used to characterize the on-flow binding of soluble human protein with 
biocompatible (dextran-based) chip-immobilized enolase. The latter method generates quantitative 
binding parameters i.e., the kinetic association and dissociation rate constants, ka and kd, and the 
equilibrium dissociation constant KD (KD = kd/ka). Moreover, it seems to be a better model for 
phenomenon studied as the enolase is immobilized in a polysaccharide environment of the candidal 
cell wall and is interacting with possibly soluble human proteins. The sensograms for the interactions 
within particular enolase-human protein pairs, analyzed in this series of experiments, are shown in 
Figure 2. The binding parameters obtained from all SPR analyzes performed throughout this entire 
study are presented in Table 1.  
Figure 1. Effects of C. albicans and C. tropicalis purified enolases (A) or anti-enolase antibody
(B) on the binding of biotin-labeled human proteins—vitronectin (VTR-Bt), fi r ectin (F -Bt),
plasminogen (HPG-Bt)—to Candi a spp. cells. Candi a spp. hyphal or pseudohyphal forms, settl d in
the w lls of a M xiSorp microplate (1 × 06 cells per well), were (A) incubated with mixtures of 40 µL
of VTR-Bt, FN-Bt or HPG-Bt (a the final mount of 2 pmoles) with 10 µL of purified Candida s .
enolases (final a t ; r ( ) pre-incubated with the fungal anti-enolase antibodies
(1 µg/µL and then treated with 50 µL of VTR-Bt, F -Bt or - t fi ).
After washing off unbound protein, the amount of bound human protein was determined using the
streptavidin-horseradish peroxidase/tetramethylbenzidine SA-HRP/TMB system. Bars represent the
mean values from three d terminat ons with standard eviations. Statistical significance levels against
the 100% controls were determine using a one-way ANOVA test: * p < 0.05, ** p < 0.01 and ** p < .001.
2.2. The Equivalent Human Protein-Binding Abilities of C. albicans Cell Surface-Exposed and Cytosolic Enolases
Two methods were utilized to compare the binding of the human VTR, FN and HPG proteins by
both the cell surface-exposed and cytosolic forms of C. albicans enolase. The overall binding levels were
first semi-quantitatively analyzed using a microplate ligand-binding assay, based on the interaction of
biotin-labeled enolase with polystyrene-immobilized human protein (Figure S4 in the Supplementary
material). Second, the advanced method of surface plasmon resonance (SPR) measurements was used
to characterize the on-flow binding of soluble human protein with biocompatible (dextran-based)
chip-immobilized enolase. The latter method generates quantitative binding parameters i.e., the kinetic
association and dissociation rate constants, ka and kd, and the equilibrium dissociation constant KD
(KD = kd/ka). Moreover, it seems to be a better model for phenomenon studied as the enolase is
immobilized in a polysaccharide environment of the candidal cell wall and is interacting with possibly
soluble human proteins. The sensograms for the interactions within particular enolase-human protein
pairs, analyzed in this series of experiments, are shown in Figure 2. The binding parameters obtained
from all SPR analyzes performed throughout this entire study are presented in Table 1.
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Neither of these two methods revealed any noticeable differences between the capability of
C. albicans surface-exposed and cytosolic enolases to interact with the human proteins being tested.
Hence, most of the subsequent experiments were performed on cytosolic enolase, under the assumption
that host proteins will interact with candidal enolases regardless of their origin.
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Table 1. Kinetic and thermodynamic parameters for the interactions of C. albicans and C. tropicalis
enolases with VTR, FN or HPG, determined by SPR measurements. The SPR-determined ka, kd and KD
values were obtained for enolase as a ligand and for human proteins as an analyte. All parameters are
presented with the standard error.
Human Protein Enolase Origin KD [M] ka [1/Ms] kd [1/s]
VTR C. albicans, cell wall 3.11 × 10−8 ± 4.58 × 10−10 1.34 × 105 ± 2.52 × 103 4.17 × 10−3 ± 7.63 × 10−5
VTR C. albicans, cytosol 5.53 × 10−8 ± 2.43 × 10−9 8.91 × 104 ± 5.06 × 103 4.93 × 10−3 ± 9.12 × 10−5
VTR C. tropicalis, cytosol 6.83 × 10−7 ± 4.39 × 10−8 1.34 × 104 ± 1.11 × 103 9.15 × 10−3 ± 5.96 × 10−4
FN C. albicans, cell wall 3.68 × 10−8 ± 3.26 × 10−9 6.03 × 104 ± 1.45 × 103 2.22 × 10−3 ± 6.74 × 10−5
FN C. albicans, cytosol 4.28 × 10−8 ± 3.74 × 10−9 6.47 × 105 ± 9.84 × 103 2.77 × 10−2 ± 3.58 × 10−3
FN C. tropicalis, cytosol 5.18 × 10−8 ± 8.54 × 10−10 5.48 × 104 ± 8.41 × 102 2.84 × 10−3 ± 6.04 × 10−5
HPG C. albicans, cell wall 1.20 × 10−7 ± 4.25 × 10−6 5.22 × 105 ± 4.84 × 104 6.26 × 10−2 ± 2.26 × 10−3
HPG C. albicans, cytosol 2.57 × 10−7 ± 4.17 × 10−6 2.70 × 105 ± 1.92 × 104 6.93 × 10−2 ± 1.30 × 10−3
HPG C. tropicalis, cytosol 2.53 × 10−7 ± 2.06 × 10−6 5.77 × 104 ± 6.84 × 103 1.46 × 10−2 ± 2.18 × 10−1
VTR: vitronectin; FN: fibronectin; HPG: human plasminogen.
2.3. C. tropicalis Enolase Binds VTR, FN and HPG with Kinetic and Equilibrium Parameters that Are
Comparable to Those of C. albicans Enolase, but Much Stronger than the S. cerevisiae Enolase
Using the microplate ligand-binding assay, we found that the cytosolic enolases isolated from
C. albicans and C. tropicalis bound to VTR, FN and HPG to a comparable degree (Figure 3). In contrast
to the candidal enolases however, the non-pathogenic yeast S. cerevisiae enolase showed a several-fold
lower binding affinity for these human proteins. Thus, we surmised that substantial structural
differences would likely exist between the Candida and Saccharomyces enolases at the regions of these
molecules that make contact with human host factors.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 7 of 28 
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Figure 3. Binding of biotin-labeled fungal enolases to microplate-immobilized VTR, FN and HPG.
Microplate wells coated with 3 pmoles of VTR, FN or HPG were filled with 50 µL of biotin-labeled
fungal enolases at increasing concentrations. The amount of bound protein was determined with the
SA-HRP/TMB system. The wells without human protein, which were surface-blocked with 3% bovine
serum albumin (BSA), served as a control, and the values obtained for these samples were subtracted
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from the total binding measurements. The bars represent the mean values ± standard deviation
(3 determinations). The levels of statistical significance were determined with one-way ANOVA in
comparison to the signal obtained for S. cerevisiae enolase; *** p < 0.001 or **** p < 0.0001.
The interactions of C. tropicalis enolase with FN, VTR and HPG were additionally analyzed by
SPR measurements. Representative sensograms from these experiments are presented in Figure 4,
and the determined binding parameters are listed in Table 1 together with those for C. albicans enolases.
For all of the candidal enolases and human proteins studied, the binding parameters—e.g., the KD
constants ranging from 10−7 to 10−8 M—were comparable and indicative of quite strong protein-protein
interactions. Interestingly however, the SPR method indicated a very poor, if any, interaction of
S. cerevisiae enolase with these three human proteins (data not shown).Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 8 of 28 
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Figure 4. SPR analysis of the interactions between C. tropicalis enolase and VTR, FN and HPG.
Sensograms were obtained after the injection of the human proteins (analyte concentrations were
within a 75–750 nM range) over a CM5 chip containing immobilized enolase at a flow rate of 30 µL/min.
A Langmuir 1:1 binding model with a baseline drift and Rmax locally was well fitted to the sensograms,
as shown by the black lines. These data were collected from three independent experiments.
2.4. The Binding of VTR, FN and HPG to the Candidal Enolases is Partially Competitive and Does Not Affect
Their Catalytic Activity
It was clearly demonstrated in our current experiments that the candidal enolases, after forming a
complex with VTR, FN or HPG, retained their enzymatic activity (a representative result is presented
in Figure S5 in the Supplementary Materials). This finding suggested that the sites of C. albicans and
C. tropicalis enolase molecules that directly interact with the human proteins are at an appreciable
distance from the enolase active center.
To initially assess for possible competition between these human proteins for binding to candidal
enolases, that would likely arise if there was any overlap between the binding sites on the enzyme
surface, we performed displacement tests in which biotinylated enolase and a molar excess of one
human protein (unlabeled) were added together to microplates containing an immobilized second
human protein. The total binding levels of the biotinylated enolase were determined and compared
to those occurring in the absence of the soluble human protein. A representative result obtained
for HPG (soluble) and VTR (immobilized) is presented in Figure S6 in the Supplementary Material.
The presence of HPG in the solution reduced the binding of the biotinylated C. albicans enolase to
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immobilized VTR by about 50%. The addition of magnesium ions, that are required for the enzymatic
activity of enolase, had no effects in these experiments.
2.5. Chemical Cross-Linking to Map the Candidal Enolase Sequence Fragments Involved in the Interactions
with Human Host Proteins
To characterize the interactions of enolase with human proteins in more detail, we applied a
chemical cross-linking method using a heterobifunctional, photoreactive reagent, sulfosuccinimidyl
2-([4,4′-azipentanamido]ethyl)-1,3′-dithiopropionate (sulfo-SDAD). In the first step, sulfo-SDAD was
attached in the dark to amino residues located on the human proteins. After subsequent incubation
with enolase, a covalent linkage of the enolase-human protein pairs occurred under UV light, with the
cross-linking agent linking to the nearest fragment of the enolase. After cleaving the disulfide bridge
in the sulfo-SDAD reagent, the proteins were digested with trypsin and the resulting peptides were
analyzed by LC-MS/MS. Using a Mass Matrix server, peptides with a mass shift corresponding to the
mass of the sulfo-SDAD fragment were searched for. The obtained results are summarized in Table 2
and the complete data set is shown in the Supplementary Materials (Table S1). This approach allowed
us to identify the reagent attachment sites and thus the putative locations of the peptides that were
involved in the analyzed interactions.
Table 2. Mass spectrometry identification of C. albicans and C. tropicalis enolase peptides involved in
the interaction with VTR, FN and HPG.
Peptides of C. albicans Enolase Peptides of C. tropicalis Enolase
VTR-Bnding
236KAGYKGKVGIAMD248
243VGIAMDVASSEFYKDGKYDLDFK265
330NPTRIKTAIEK340
419IEEELGSEAIYAGK432
236QAGHTGKVKIAMDPASSE253
245IAMDPASSEFFKDGKYDLDFK265
334IKKAIEKK341
FN-Binding
52DGDKSK57
107LGANAILGVSLAAANAAAAAQGIPLYKHI
ANISNAKK143
187IGSEVYHNLK196
240KGKVGIAMDVASSEFYKDGK259
245IAMDPASSEFFKDGKYDLDFK265
334IKKAIEKK341
HPG-Binding
30GLFRSIVPSGASTGVHEALELRDGDK55
56SKWLGKGVLK65
107LGANAILGVSLAAANAAAAAQGIPLYK133
237AGYKGKVGIAMDVASSEFYKDGK259
106KLGANAILGVSLAAA120
222TPEEALDLIVESIEQAGHTGK242
245IAMDPASSEFFKDGK259
A sulfo-SDAD cross-linking reagent with a disulfide bridge was added to each human protein preparation and
the whole mixture was incubated with fungal enolases. After the formation of a covalent bond for the fungal
protein-human protein pairs, the disulfide bond was reduced and the released proteins were digested with trypsin
or, occasionally, endoproteinase Glu-C. The obtained peptides were then analyzed using a Dionex Ultimate 3000
UHPLC system coupled to an HCTUltra ETDII mass spectrometer. Within the panel of selected peptides, amino acids
were highlighted for which mass shifts due to the interaction with sulfo-SDAD were indicated. These peptides were
then analyzed using the Mass Matrix software. The sequences of peptides that were reproducibly identified in three
independent experiments are presented.
For the interaction with VTR, four peptides on C. albicans enolase and three peptides on
C. tropicalis enolase were identified, suggesting that the sequence fragment 334IKTAIEK/IKKAIEK340,
and 236KAGYKGK VGIAMDVASSEFYKDGKYDLDFK/QAGHTGKVKIAMDPASSEFFKDGKYDLDFK265
contribute to the VTR-contact area in both enolases. For the enolase-FN pairs, four peptides
from C. albicans enolase and two from C. tropicalis enolase were identified, indicating a common
sequence 245IAMDVASSEFYKDGK/IAMDPASSEFFKDGK259 in the FN-binding region in both
enzymes. For the interaction of HPG, four and three peptides on C. albicans and C. tropicalis
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were found, with the common sequences 107LGANAILGVSLAAA120, 237AGYKGK/AGHTGK242
and 245IAMDVASSEFYKDGK/IAMDPASSEFFKDGK259 putatively identified as contributing to the
HPG-binding area. We finally concluded that the long sequence 236KAGYKGKVGIAMDVASSEFY
KDGK/QAGHTGKVKIAMDPASSEFFKDGK259 is a consensus site for enolase binding of all three
human proteins studied.
An inverted setup for cross-linking experiments, i.e., one in which first enolase reacted with
sulfo-SDAD in the dark, followed by linking to human protein under UV light, was applied for VTR and
HPG binding by candidal enolases, revealing one peptide from VTR—198DVWGIEGPIDAAFTR212—and
two from HPG—48ECAAKCEE55 and 520TNPRAGLE527—that putatively interact with candidal enolases.
2.6. Molecular Modeling of the C. albicans Enolase Interactions with VTR, HPG and Fragments of FN
Enolase fragments involved in the interactions with human proteins—VTR, FN and HGP—were
mapped and structural models for these interactions were developed using the ClusPro 2.0:
protein–protein docking software (Boston University). The docking was performed for the C. albicans
enolase dimeric structure (obtained using homology modelling based on the template PDB ID:
1EBH [58]) and the full-length HPG structure (Research Collaboratory for Structural Bioinformatics
Protein Data Bank, PDB ID: 4DUU [59]), FN fragment (PDB ID: 3M7P [60]) and the VTR structure
obtained using the Schrödinger Prime software (LLC) based on the multiple templates (PDB ID: 3C7X,
1OC0, 2JQ8 and 3BT1 [61–64])
The model presented in Figure 5 indicates that the four identified enolase peptides and one VTR
peptide, denoted in red and grey, respectively, are indeed involved in the interactions between these
proteins. Interestingly, the active center of enolase (marked in yellow) does not interact with VTR
and is unoccupied in this model, consistent with the above results indicating that the binding to host
proteins does not affect the enzymatic activity of enolase.
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Figure 5. Proposed model of the interaction between C. albicans enolase (green) and human VTR
(purple). The docking was perfor ed for the C. albicans enolase dimeric structure (template PDB
ID: 1 [58]) and VTR structure obtain based on multiple templates (PDB ID: 3C7X, 1OC0,
2JQ8 and 3BT1 [61–64]). The enolase peptides and the VTR p ptide identified in the chemical mapping
experiments are indicated in red and gra , r ti ely. The active sit residues of the catalytic center
of enolase are indicated in yellow. The 3 olecular model is presented in a wall-eyed stereo view.
An additional file Enolase_VTR.mpg with the PyMOL-generated video presentation of this model is
attached to the article together with the Supplementary Materials (Video S1).
In the case of enolase interactions with FN, chemical cross-linking experiments did not allow us
to map the enolase-binding region due to the size, strong glycosylation and still unresolved structure
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of the whole FN protein. A 308 amino acid fragment of FN (PDB structure: 3M7P [60]) was used for
molecular modeling, and two different models were thereby proposed for its interaction with enolase.
The models were verified by the direct interaction of the FN fragment with the peptides identified on
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Figure 6. Stereo image (wall-eyed) of the interaction between C. albicans enolase and human FN.
The docking was performed for the C. albicans enolase dimeric structure (template PDB ID: 1EBH [58])
and FN fragment (PDB ID: 3M7P [60]). The two models for the protein-protein interaction between a
human FN fragment (black and pink) and C. albicans enolase (green with active site residues of the
catalytic center indicated in yellow) were generated using ClusPro 2.0: protein-protein docking software.
The enolase peptides identified in the chemical mapping experiments are marked in red. Additional files
Enolase_FN_1.mpg and Enolase_FN_2.mpg with the PyMOL-generated video presentations of these
models are attached to the article together with the Supplementary Materials (Videos S2 and S3).
As mentioned above, five peptides on C. albicans enolase were identified from cross-linking analysis
of the interaction with HPG (marked in red in Figure 7), but the subsequent molecular modeling did not
confirm any involvement in this interaction for one of them—30GLFRSIVPSGASTGVHEALELRDGDK55.
Interestingly, a comparison of the amino acid sequences of fungal enolases indicated that this sequence
region is identical in the C. albicans and S. cerevisiae enzymes (Figure 8).
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Figure 7. Proposed model of the C. albicans enolase interaction with human HPG. The docking was
performed for the C. albicans enolase dimeric structure (template PDB ID: 1EBH [58]) and HPG structure
(PDB ID: 4DUU [59]). The enolase dimer is indicated in green and HPG is denoted in blue. The enolase and
HPG peptides identified in the chemical mapping experiments are marked in red and gray, respectively.
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The active site residues of the catalytic center of the enolase are highlighted in yellow. The 3D
molecular model is presented in a wall-eyed stereo view. An additional file Enolase_HPG.mpg with
the PyMOL-generated video presentation of this model is attached to the article together with the
Supplementary Materials (Video S4).
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Figure 8. Comparison of the putative human protein binding sites on the C. albicans, C. tropicalis,
and non-pathogenic S. cerevisiae enolases. Alignment of the enolase amino acid sequences from
C. albicans (accession number P30575), C. tropicalis (accession number C5MD83) and S. cerevisiae
(accession number P00929). Peptides identified during chemical crosslinking involved in the interaction
with HPG are marked in a gray background, with VTR are marked with red letters, and with FN are
highlighted by underlines.
2.7. The Sequence Fragment 235DKAGYKGKVGIAMDVASSEFY255 of C. albicans Enolase is a Major
Determinant of Its Interactions with Human Proteins
The full amino acid sequence of the enolase from C. albicans shows a high degree of homology
to the C. tropicalis (82.5%) and S. cerevisiae (77.5%) enolases (Figure 8). Considering the results of our
chemical cross-linking mapping of enolase interactions with VTR, FN and HPG, combined with
the sequence alignments shown in Figure 8, a single enolase peptide fragment was found
to be involved in the interaction with all three human proteins tested in our current study.
Interestingly, this fragment—235DKAGYKGKVGIAMDVASSEFY255—is significantly different from the
corresponding sequence in S. cerevisiae enolase which, as mentioned above, interacts weaklier with
human proteins.
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To evaluate the significance of this fragment, recombinant proteins were obtained i.e., full-length
C. albicans enolase (R-Eno) and C. albicans enolase in which the 235DKAGYKGKVGIAMDVASSEFY255
sequence was replaced with the corresponding sequence of S. cerevisiae enolase (R-Enosc)—234KAAGHD
GKIKIGLDCASSEFF254. After purification, the enolases were labelled with biotin and analyzed for their
binding to microplate-immobilized human proteins. Based on these tests, a reduction in binding by more
than 50% was found for R-Enosc compared to R-Eno, for which the obtained level of human protein
binding was given a reference value of 100% (Figure 9). These experiments, independently of other data
presented in this study, confirmed the important role of this sequence fragment in the interactions of
candidal enolases with human host proteins.
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Figure 9. Binding of biotin-labeled recombinant fungal enolase to microplate-immobilized VTR, FN and
HPG. Microplate wells coated with 3 pmoles of VTR, FN or HPG were filled with 50 µL of biotin-labeled
recombinant enolases in increasing concentrations. The absorbance intensities were measured after
the washing of unbound proteins. The results obtained during the control experiment (non-human
protein surface blocked with 3% BSA solution) were subtracted from the total binding measurements.
The bars represent the mean values ± standard deviation (3 determinations). Statistical significance
was determined using one-way ANOVA; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
3. Discussion
The numerous intracellular proteins, including housekeeping enzymes, chaperones, translation factors,
DNA-binding proteins and many others, that are non-conventionally secreted and reside on the cell
surface wher they act s receptors for soluble proteins or small molecules, comprise th largest subset
of moonlighting proteins [65]. Enolase is a prominent representative f this multifunctional protein
class and h s been reported to be exposed on the s rface of d verse prokaryotic and eukaryotic cells.
Th cell surface-bound form of human enolase can contribute to various on-inf ctious pathological
conditions [1–3]. Th enol es expressed on bacterial [21] and eukaryotic [23,24] pathog ns have be n
c nfi med as virulence factors.
The presen e f enolase on the cell wall of Candida spp. has b en reported in a number of previous
studies [25–27,38,40,66–68]. However, the mechani ms nderlying the presence and relatively stable
attac ment of candidal enolase at cell wall have not yet been identifi d. Current hypotheses include
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a sorting role of the 169 amino acid N-terminal domain of this enzyme [25] or the transport of enolase
among the cargo of extracellular vesicles [69].
We aimed in our current study to structurally characterize the interactions between candidal
enolases and selected human host proteins that would reflect two of the major functions that enolase and
numerous other moonlighting proteins perform on the cell surfaces of various microbial pathogens, i.e.,
the adhesion to human host tissues and the interference with host homeostatic/hemostatic proteolytic
cascades (reviewed in: [7]). The generally accepted model proteins used to probe for moonlighting
adhesion functions have been proteinaceous ECM components such as FN, VTR, collagen, LAM (for
examples see [70–72]). VTR and FN are also present in blood. Although only in qualitative terms,
the binding of these host ligands by candidal enolase has been described by us previously [45]. On the
other hand, the binding of HPG by cell-surface proteins is a very general phenomenon, observed in a
variety of mammalian cells, and in eukaryotic and bacterial pathogens (for a recent review see [3]).
Our present study supports the previously suggested hypothesis that candidal enolase contributes to
the activation of fibrinolysis and plasmin-dependent ECM degradation during candidiasis [46–48].
We had further noted in this regard that enolase had been confirmed as one of multiple HPG-biding
proteins at the candidal surface [48,50,51].
We used several preparations of enolase in our current experiments: natural enolases purified from
the cytosol or cell wall of C. albicans and C. tropicalis, and, for comparative purposes, a commercially
available natural enolase from S. cerevisiae. Initially, using tests with whole candidal cells, we confirmed
a significant (20–40%) contribution of cell surface enolase to the total binding of VTR, FN or HPG
(Figure 1), despite the known co-occurrence of a vast array of both true (i.e., GPI-anchored) and
moonlighting adhesins at the candidal cell wall. At the pure protein-protein level, the binding of isolated
candidal enolases to VTR, FN and HPG was analyzed using two different methods. For comparative
purposes, a semi-quantitative estimation of the overall binding level using a microplate test for
the interaction of biotin-labelled enolase with polystyrene-immobilized human protein has usually
been sufficient. In more rigorous evaluations, quantitative binding parameters (the association and
dissociation rate constants ka and kd, and the equilibrium dissociation constant KD) were calculated
from SPR measurements, thereby indicating relatively strong interactions between the fungal and
human proteins, with the KD constants ranging from 10−7 to 10−8 M. The applied method of chip
surface regeneration (1 M NaCl) suggests that electrostatic forces can be the major determinants of
the protein-protein interactions studied. The dissociation constants were within the same range,
as determined using the SPR method for the binding of HPG and FN to Streptococcus suis enolase [73],
by biolayer interferometry for the interactions of Aspergillus fumigatus enolase with HPG [74], and by SPR
measurements for the interactions of candidal enolases with the components of plasma kinin-forming
system [68,75]. Somewhat surprisingly, as determined by the SPR method, the interactions of human
proteins—HPG, FN, LAM, and kininogen—with dedicated adhesins covalently linked to the candidal
cell wall—Als1, Als7, Hyr, Epa1, and Epa6—were not previously found to be stronger than the
moonlighting enolase-dependent interactions [49,67,76–78]. This further supported the hypothesis
that fungal cell wall-associated enolase plays a remarkable role in the adherence of fungal pathogens
to human host tissues.
One of the important findings in this part of our study was that the strengths of the interactions
between all three human proteins we tested with cell surface-bound and cytosolic forms of candidal
enolase were indistinguishable, thus excluding the possibility that the moonlighting adhesin function of
enolase is acquired upon the transfer of this enzyme from the cytosol to the cell surface and possibly due
to some significant changes to this protein’s covalent structure or conformation, and/or posttranslational
modifications that occur exclusively for cell wall enolase. The candidal cell surface enolase has an
identical molecular mass and specific enzymatic activity as the cytosolic form, thus confirming
that all of the structural elements essential for the evolutionally conserved catalytic function are
preserved following non-conventional enzyme secretion. An accidental glycosylation that could
occur if enolase “illegally” enters the classical secretion membrane system [23] was also excluded.
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Several posttranslational modifications at specific amino acid residues were previously identified for
human enolase in various severe diseases [79,80], and also in the enolase from the Plasmodium falciparum
parasite [81]. Analogous modifications at corresponding residues in candidal enolases, even if they
occur [40], are unlikely to underly the moonlighting adhesin function of the altered enzyme, as the
recombinant C. albicans enolase produced in E. coli was shown to bind the three human proteins we
analyzed in a comparable manner to the naturally occurring enzyme. Thus, we conclude that the
structural determinants critical for the binding of host proteins by the enolase at the candidal cell
surface are inherent also to the enolase molecules present in the cytosol.
We did not observe any remarkable differences in the VTR-, FN- and HPG-binding strength and
capacity between the enolases from C. albicans and C. tropicalis. The moonlighting binding ability
of candidal cell surface proteins towards various ECM/blood proteins was reported in our previous
study in C. parapsilosis and C. glabrata [45,49,78]. Thus, we hypothesized in our present report that the
moonlighting adhesion function of enolase would be conserved within the Candida genus. The amino
acid sequences of C. albicans and C. tropicalis enolases are 82.5% identical. In some protein families,
very small sequence differences can generate a moonlighting function of one member, in the absence of
this property in the others [53,54]. It was evident from our present data that the differences between
the amino acid sequences of the candidal enolases (Figure 8) are not sufficiently concentrated at the
areas on this protein molecule that come into a tight contact with human VTR, FN or HPG in the
formed complexes.
On the other hand, the enolase of a non-pathogenic yeast that shares 77.5% identical amino acid
residues in the sequence with C. albicans enolase, presented much weaker, if any, binding to VTR, FN and
HPG. These observations support the hypothesis that the capability of enolase to interaction with host
proteins is particularly strongly evolved in pathogenic yeasts and makes important contributions to
their virulence. The sequence alignment of the enolases of Candida spp. and S. cerevisiae (Figure 8)
did not initially reveal a candidate sequence fragment that can lie in the contact area between the
enolase and human proteins, based on the absence of at least several specific amino acid residues in
the non-pathogenic yeast enolase.
The main aim of our current study was to present structural models for the interaction of candidal
enolase with three human proteins that we chose to probe the major moonlighting functions of this
intracellular/secreted enzyme at the pathogen cell surface. For this purpose, we used a three-step
strategy involving: (i) mapping the peptide sequences, potentially involved in enolase interactions with
human proteins by chemical cross-linking and mass spectrometric analysis; (ii) molecular modelling
of VTR-, FN- and HPG-enolase complexes; and (iii) confirming the model by substituting, in the
recombinant candidal enolase, the sequence critical for the interactions with human proteins with the
corresponding peptide in S. cerevisiae enolase.
For assessing the interactions of enolase with human ECM proteins, no structural data have been
yet published for this enzyme from any organism. To our knowledge, no such analyses regarding
the binding of ECM components have been performed for any moonlighting protein. By chemical
cross-linking analyzes, we identified a number of peptides that putatively interact with VTR and
FN (Table 2), all containing positively charged lysine residues and located at some distance from
the catalytic active site of enolase. Some of these seemed to contribute to the binding of VTR
and FN. The longest sequence fragment that putatively interacted with both of these proteins was
236KAGYKGKVGIAMDVASSEFYKDGK259. From the perspective of enolase as a ligand, for complex
formation with VTR, our cross-linking data were sufficient to identify a VTR fragment that putatively
comes into contact with enolase—198DVWGIEGPIDAAFTR212.
In the next step of our analyses, using available bioinformatics platforms and taking into account
the results of our earlier cross-linking-based mapping, structural models for the complexes of enolase
with our chosen human host proteins were developed. The entire VTR molecule and an FN fragment
(aa 297–604) were docked to candidal enolase dimeric molecules, modelled on the basis of the known
crystal structure of enolase from S. cerevisiae, with two identical subunits facing each other in an
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anti-parallel manner [82]. In the finally developed models (Figures 5 and 6), the contact region between
enolase and the ECM proteins was clearly spaced from the enzyme active center. In the enolase-VTR
complex, some peptides identified in the two proteins by cross-linking were found to make contact
with each other, thus elegantly validating the model. In the case of VTR, the cross-linking experiments
identified that the fragment 198DVWGIEGPIDAAFTR212 that interact with fungal enolase are located in
the central hemopexin-like domain (aa 131–342). This domain is known to bind numerous ligands such
as heparin, type I collagen, β-endorphin, cholesterol sulphate, or complement complex. In addition,
hemopexin-like repeats are known binding sites for Streptococcus pyogenes cells [83]. In our present
models, as could be expected, the spots on enolase that face VTR and FN extensively overlap.
Being a universal binding phenomenon that contributes to the virulence of many pathogenic
microbes [84–87], the interactions of enolase with HPG has been much better characterized in molecular
terms. Two C-terminal lysine residues were suggested to be the main sites involved in HPG binding
by the enolases of humans and various pathogens [88]. Confirmations of their role were obtained by
site-directed mutagenesis of the enolases of several bacterial species where the substitutions of leucine
or alanine residues for the critical lysine residues resulted in a two-fold decrease in HPG binding [87–90].
In addition, the role of an internal HPG-binding motif in enolases—248FYDKERKVY256—was proposed
for many organisms, including parasites and bacteria, however, in most cases, only on the basis
of amino acid sequence comparisons [91–95]. For two species only—Streptococcus pneumoniae and
Leishmania mexicana, the role of this internal enolase motif was experimentally supported by a
competitive inhibition assay with synthetic peptides and also by site-directed mutagenesis of the
binding motif [91,92]. The replacement of three amino acid residues in the selected fragment of the
bacterial enolase (Lys251Leu, Glu252Gly and Lys254Leu substitutions) reduced HPG binding to 44% of
the wild-type level, whilst the additional deletion of the C-terminal lysine residues did not further
reduce this binding. Hence, this internal motif within bacterial enolases appears to be crucial in the
binding process [91]. The fact that the same HPG binding motif has been identified in different species
suggests that it may also be relevant for other pathogenic organisms [85].
In our current cross-linking analyses, we identified four candidal enolase peptides that seemed to
interact with HPG, all containing lysine and, occasionally, arginine residues (Table 2). Similar to the
enolase sites that were responsible for complex formation with VTR and FN, these peptides were located
outside of the enzymatic active center. Interestingly, the 237AGYKGKVGIAM DVASSEFYKDGK259
sequence was again identified as a common long fragment essential for enolase binding to all of the
human proteins under study.
For molecular modeling of the candidal enolase-HPG complex, the full length HPG protein was
docked to the modelled dimeric candidal enolase, and the results of cross-linking experiments were
also considered. The model obtained from this (Figure 7) shows that HPG adheres to enolase at a
similar area as VTR and FN, far away from the enzyme active center. It was not surprising that there
would be little room for evolutional variations to accommodate different and large proteinaceous
ligand binding at very different areas of the enolase molecule if the evolutionally conserved catalytic
role of enolase in central metabolism was to be preserved.
The binding of HPG to mammalian and bacterial cells was reported to be mediated by kringle
domains that have an affinity for lysine [96,97]. One of the HPG peptides we here identified
—520TNPRAGLE527—is located within kringle domain 5, additionally confirming that the binding of
HPG to C. albicans enolase is lysine dependent [92,98].
As mentioned above, S. cerevisiae enolase binds VTR, FN and HPG with a much lower affinity
than the candidal enolases. Notably however, sequence comparisons for these proteins (Figure 8)
revealed a similarity between the major identified sequence fragments, with differences in only few
amino acids. At the positions of the lysine residues in C. albicans enolase important for HPG binding
(Lys236) and VTR/FN binding (Lys240), a negatively charged aspartic acid residue and non-polar alanine
residue is present in the S. cerevisiae enzyme. Finally, to confirm that role of the enolase sequence
fragment—235DKAGYKGKVGIAMDVASSEFY255—in the binding of VTR, FN and HPG, this sequence
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was substituted in a recombinant candidal protein for the corresponding S. cerevisiae enolase sequence.
At least a two-fold reduction of VTR-, FN- and HPG-binding was observed in the resulting mutant
protein compared with the wild-type protein (Figure 9). A complete abolishment of the interactions
studied was not something to be expected, as the high affinity with which candidal enolase binds
human proteins seems to be an additive effect i.e., involving the participation of all binding regions
with a particular role of positively charged lysine residues. A confirmation of this hypothesis may
be the Thr142 to Lys143 exchange between two recombinant enolases resulting in the location of two
lysine residues side-by side in the candidal enzyme. Thus, our current study has provided molecular
data that may fit into a previously proposed general rule for the interactions of moonlighting proteins
with their non-canonical ligands [53] i.e., that relatively small changes in the enolase sequence may
contribute to the engagement of this protein as a contributing factor in the pathogenic features of
Candida spp. yeasts.
4. Materials and Methods
4.1. Yeast Strains and Culture Conditions
The C. albicans strain ATCC® 10231™, and C. tropicalis strain T1 (ATCC® MYA-3404™) were
purchased from American Type Culture Collection (Manassas, VA, USA). Yeast cultures were incubated
in YPD medium containing 1% yeast extract, 2% soybean peptone and 2% glucose at 30 ◦C for 16 h
with shaking at 170 rpm (MaxQ 4000, Thermo Fisher Scientific, Waltham, MA, USA). To induce the
hyphal or pseudohyphal forms of C. albicans and C. tropicalis, respectively, further culturing was carried
out in RPMI 1640 medium at 37 ◦C for 72 h with shaking at 170 rpm.
4.2. Commercial Proteins
Human VTR was purchased from R&D Systems (Minneapolis, MN, USA), human FN, HPG and
S. cerevisiae enolase from Sigma-Aldrich (St. Louis, MO, USA), bovine serum albumin (BSA)
from BioShop Canada Inc. (Burlington, ON, Canada), β-1,6-glucanase from Takara Bio Inc. (Otsu,
Shiga, Japan), trypsin and endoproteinase Glu-C from Promega (Madison, WI, USA), horseradish
peroxidase-conjugated streptavidin (SA-HRP) solution from MP Biomedicals (Solon, OH, USA),
monoclonal mouse anti-fungal enolase antibody from Invitrogen (Thermo Fisher Scientific) and
enterokinase from MyBioSource (San Diego, CA, USA).
4.3. Purification of C. albicans Surface-Exposed Enolase
After culturing C. albicans in RPMI 1640 medium, preparations of cell surface-exposed proteins
were obtained by β-1,6-glucanase treatment according to our previously described method [49].
Briefly, the first step in the purification procedure was ion-exchange chromatography. The isolated
fungal protein mixture (10 mL), pre-dialyzed against 20 mM Tris-HCl buffer, pH 8.0, was loaded
onto a ResourceTM Q 1 mL column (GE Healthcare, Uppsala, Sweden) equilibrated with the same
buffer. Adsorbed proteins were then eluted in a linear gradient of 0–0.5 M NaCl (20 mL) at a flow
rate of 1 mL/min [49]. The collected fractions were analyzed by SDS-PAGE and those that showed
strong bands corresponding to the molecular mass of enolase (47 kDa) were subjected to the next
purification step—gel filtration on a TSK G 3000 SW (21.5 mm × 30 cm, particle size 13 µm) column
(Tosoh Bioscience, King of Prussia, PA, USA). The column was eluted with 0.1 M sodium sulphate/0.1 M
sodium dihydrogen phosphate, pH 6.7, and the collected fractions were characterized by SDS-PAGE,
and analyzed by LC-MS/MS using our previously published protocols [49]. The enolase-containing
fractions were finally subjected to chromatofocusing on a MonoP HR 5/20 column (GE Healthcare),
equilibrated with 25 mM Bis-Tris-iminodiacetic acid buffer, pH 7.1, and further eluted in a linear
gradient of 10% Polybuffer 74 in 20 mM Bis-Tris-iminodiacetic acid buffer pH 7.1 (Sigma-Aldrich), in a
total volume of 20 mL, at a flow rate of 0.5 mL/min. The collected fractions were next individually
loaded onto a Superdex 200 HR 10/50 column (Amersham Biosciences, Uppsala, Sweden) in 20 mM
Int. J. Mol. Sci. 2020, 21, 7843 17 of 27
Tris-HCl pH 6.7 at a flow rate of 0.5 mL/min to separate the proteins from ampholytes. The enolase
purity and identity were confirmed by SDS-PAGE and LC-MS/MS analysis.
4.4. Purification of the Cytosolic Enolases from C. albicans and C. tropicalis
The fungal cytosolic enolases were purified using a previously described strategy [75],
in accordance with the method of Ballantyne and Warmington, with some modifications [99]
Briefly, Candida spp. cells were grown in YPD medium at 30 ◦C for 16 h with shaking at 170 rpm.
After centrifugation (2-16KL, Sigma-Aldrich, 1600× g, 3 min) and washing of the cell pellet twice
with phosphate-buffered saline (PBS), pH 7.4, the cells were suspended in water with protease
inhibitors (Complete Tablets EDTA-free, EASYpack, Roche, Penzberg, Germany) and sonicated in a
Sonic Ruptor 250 Ultrasonic Homogenizer (Omni International, Tulsa, OK, USA) for 6 min, with the
amplitude set at 0.5. The resulting protein solution was subjected to ammonium sulphate fractionation,
with the first saturation to 65% and discard of the pellet, and the second saturation of the resulting
supernatant to 100%. After centrifugation (13,000× g, 20 min), the supernatant was discarded and
the pellet was dissolved in 20 mM Bis-Tris buffer, pH 6.4, dialyzed overnight against the same buffer,
and separated on a MonoQ 1 mL column (Pharmacia Biotech, Piscataway, NJ, USA) using a linear
gradient of 0.5–1 M NaCl (80 mL). Fractions with enolase activity (see below) were collected and
dialyzed overnight against 10 mM sodium acetate buffer, pH 4.8. The final enolase purification was
performed on a MonoS 1 mL column (GE Healthcare) and a linear gradient of 0–1 M NaCl (75 mL).
The enolase purity and identity were confirmed by SDS-PAGE and LC-MS/MS analysis.
4.5. Expression and Purification of Recombinant C. albicans Enolase (R-Eno)
After culturing in YPD medium, the yeast cells were dissolved in TRI®Reagent (Sigma Aldrich).
After adding glass beads (425–600 µm, Sigma Aldrich), the cells were ruptured using the FastPrep
device Precellys Evolution (Bertin Technology, Montigny-le-Bretonneu, France) for 2 cycles at 45 s
each and a 6.0 RPM speed. The total RNA was extracted in accordance with the protocol provided
with the TRI®Reagent, followed by the synthesis of the cDNA strand using 2 µg total RNA, 0.5µg of
oligonucleotide (dT)18 primer and 200 U of MLV reverse transcriptase (Moloney murine leukemia
virus reverse transcriptase; Promega). The complete coding region of the C. albicans enolase gene was
amplified by PCR using the C1000 Touch Thermal Cycler (Bio-Rad, Hercules, CA, USA), using the
specific primers: forward, 5′GGTGATGATGATGACAAGATGTCTTACGCCACTAAAATC3′ and
reverse, 5’GGAGATGGGAAGTCATTATTACAATTGAGAAGCCTTTTG3’. The reaction conditions
were as follows: 95 ◦C for 2 min, followed by 30 cycles of 95 ◦C for 30 s, 52 ◦C for 30 s, 74 ◦C for 3 min
and 74 ◦C for 10 min. PCR products were electrophoretically verified in a 1% agarose gel.
Enolase expression constructs were prepared using the aLICator LIC Cloning and Expression
Kit (Thermo Fisher Scientific) according to the manufacturer’s instructions. Briefly, PCR products
were purified using the Gel-Out Concentrator Kit (A&A Biotechnology, Gdynia, Poland) and then
incubated with T4 DNA Polymerase in LIC buffer for 5 min. The reaction was stopped by the addition
of EDTA to a final concentration of 30 mM. The pLATE51 expression vector harboring an N-terminal
6xHis tag and an enterokinase protease cleavage site was next added and the mixture was incubated
for 5 min at room temperature. This annealed mixture was used directly to transform E. coli TOP10
(Thermo Fisher Scientific) cells. Positive transformants were selected for their resistance to ampicillin
(100 µg/mL). Plasmids were isolated using the Mini Plasmid kit (A&A Biotechnology), and after
sequence verification (Genomed, Warsaw, Poland) were used to transform chemically competent
RosettaTM 2 (DE3) E. coli cells. The overnight culture was inoculated into tryptic soy broth (TSB)
medium containing ampicillin (100 µg/mL) and chloramphenicol (34 µg/mL). The resulting bacterial
cultures were grown at 37 ◦C to the middle logarithmic phase and the expression of C. albicans enolase
was induced with 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) whilst maintaining the cells at
30 ◦C for 3 h. After cell lysis by sonication (10 min, 0.8 amplitude), the supernatant and pellet fractions
were separated by centrifugation (20,000× g at 4 ◦C for 30 min). The recombinant protein was purified
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using a strategy similar to that previously described [68]. Briefly, during the first step of purification,
the supernatant, containing the recombinant protein (His6-enolase) was loaded onto an Ni–NTA
Sepharose High Performance affinity matrix 2 mL column (GE Healthcare). Fractions containing
enolase were diluted to a final protein concentration of 0.5 mg/mL with an appropriate volume of
enteropeptidase cleavage buffer. In accordance with the manufacturer’s protocol, the enzyme was
added in a ratio of 50 µg protein:1 U enterokinase. After 20 h, the mixture was again loaded onto an
Ni-NTA Sepharose column and the tag-free enolase was subjected to ion-exchange chromatography on
a MonoQ 1 mL column (Pharmacia Biotech). Finally, the purity of the selected fractions was verified
by SDS-PAGE and an activity assay was performed (see below).
4.6. DNA Construct for R-Enosc Expression
The construct used for R-Enosc expression was prepared by substitution of a fragment
of C. albicans enolase coding sequence with a corresponding coding sequence fragment of
S. cerevisiae enolase. The final recombinant coding sequence of C. albicans enolase with the
coding sequence fragment of S. cerevisiae enolase (nucleotide sequence: AAGGCTGCTGGTCACGA
CGGTAAGATCAAGATCGGTTTGGACTGTGCTTCCTCTGAATTCTTC, amino acid sequence:
234KAAGHDGKIKIGLDCASSEFF254), together with a fragment encoding the WELQut protease
cleavage site upstream of the enolase coding sequence, was synthesized and cloned into the existing
open reading frame of the pETDuet-1 vector between the BamHI and XhoI restriction sites (GenScript,
Piscataway Township, NJ, USA). The obtained plasmid construct was used for bacterial transformation
and positive transformants were selected. The plasmid was isolated using a Plasmid Mini Kit
(A&A Biotechnology) and used to transform chemically competent RosettaTM 2 (DE3) cells (Novagen).
The further steps taken in relation to protein expression and purification were analogous to those used
for C. albicans recombinant enolase (R-Eno).
4.7. Enolase Activity
Enolase activity was analyzed using a colorimetric assay kit (Sigma-Aldrich) following
the manufacturer’s instructions. In the assay, enolase converts D-2-phosphoglycerate into
phosphoenolpyruvate, which further reacts with peroxidase substrate to form a colored product
with an absorbance at 570 nm, which is measured for 1 h with 3 min intervals (using a Synergy H1
microplate reader; BioTek, Winooski, VT, USA). In one experiment, a modification was introduced i.e.,
before measuring its activity, enolase at a final concentration of 20 nM was incubated with VTR, FN,
and HPG at a 1:1 molar ratio for 60 min in PBS at 37 ◦C, with gentle shaking. Wells without human
protein constituted the reference control equating to 100% enolase activity. One unit (U) of enolase is
the amount of enzyme that generates 1.0 µmole of H2O2 per minute at pH 7.2, 25 ◦C.
4.8. Labeling of Human Proteins and Purified Enolases
For biotin labeling of FN (FN-Bt), VTR (VTR-Bt), HPG (HPG-Bt), R-Eno (R-Eno-Bt) and R-Enosc
(R-Enosc-Bt), a solution of N-hydroxysuccinimide ester of biotin (NHS-biotin, Sigma-Aldrich) in
dimethylformamide (1 mg/100 µL) was added, maintaining a ratio of 10 µg NHS-biotin per 50 µg
protein. The prepared reaction mixture was incubated for 4 h at 4 ◦C and then dialyzed against PBS at
4 ◦C for 24 h.
4.9. Competition of Human VTR, FN and HPG with Soluble Enolase or Anti-Fungal Enolase Antibody for the
Binding to C. albicans or C. tropicalis Cells
Competition binding assays were performed in MaxiSorp 96-well microtiter plates (Nunc, Roskilde,
Denmark), in which Candida spp. cells (1 × 106 cells per well) were grown in RPMI 1640 medium
for 3 h at 37 ◦C. After each step, the cells were washed three times with 200 µL PBS, pH 7.4,
additionally containing 1% BSA. The unoccupied well surface was blocked with 300 µL of 3% BSA in
PBS for 1 h at 37 ◦C. Subsequently, 2 pmoles of VTR-Bt, FN-Bt or HPG-Bt (40 µL) and 24 pmoles of
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unlabeled purified enolases (10 µL) were added to the wells together, and the plate was incubated for
1.5 h at 37 ◦C with gentle mixing. The amount of bound biotinylated ECM protein was determined
using SA-HRP and the peroxidase substrate 3,3′5,5′-tetramethylbenzidine (TMB) (Sigma-Aldrich),
as described previously [100]. The 100% relative binding control reference constituted the wells in
which enolase samples (10 µL) were replaced with PBS (10 µL).
The competition assay with antibodies was performed similarly with some minor modifications.
Briefly, after blocking the unoccupied wells with 3% BSA, 1 µg/µL anti-fungal enolase antibody solution
was added to the fungal cells. The mixture was then incubated for 1 h at 37 ◦C. After washing three
times with PBS, solutions of biotinylated human proteins were added (250 nM in a total volume of
50 µL per well) and incubated for 1.5 h at 37 ◦C.
4.10. Semi-Quantitative Analysis of Enolase Binding to Microplate-Immobilized VTR, FN, and HPG
The binding assays for C. albicans, C. tropicalis and S. cerevisiae enolases, and the recombinant
enolases—R-Eno and R-Enosc, were also performed using MaxiSorp 96-well microtiter plates (Nunc) in
which the human proteins were immobilized via an overnight incubation at 4 ◦C (3 pmol protein per
well). Following this and all subsequent steps, the wells were washed three times with 1% BSA in PBS.
The unoccupied surface in each well was blocked overnight with 3% BSA in PBS at 4 ◦C. Samples of
biotinylated enolase solutions at increasing concentrations in the range of 10–500 nM (50 µL in PBS)
were then added to the wells and incubated for 1.5 h at 37 ◦C. After washing out the unbound proteins,
the binding levels were detected with the SA-HRP/TMB system.
4.11. SPR Characterization of Fungal Enolase Binding to VTR, FN and HPG
Kinetic and thermodynamic analyses of the binding of fungal enolases to VTR, FN and HPG
were carried out with a BIACORE 3000 system (GE Healthcare). First, for the activation of carboxyl
groups present on the CM5 sensor chip (GE Healthcare), an Amine Coupling Kit (GE Healthcare) was
used, i.e., a mixture of 50 mM 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and 200 mM
N-hydroxysuccinimide (NHS). Next, the immobilization of surface or cytosolic C. albicans enolases
and cytosolic C. tropicalis enolase was performed at 25 ◦C with a flow rate of 10 µL/min in an acetate
buffer at pH 4.5 to a level of 300 RU units. In the final step, carboxyl groups not involved in protein
immobilization were blocked with 1 M ethanolamine solution, pH 8.5. The binding levels/ strength
analyses for VTR, FN or HPG were performed at 25 ◦C in a buffer containing 10 mM HEPES, 150 mM
NaCl and 0.005% (w/v) P20 surfactant, pH 7.4. After introducing the proteins above the chip surface,
a 2-min association and 2-min dissociation occurred at a flow rate of 30 µL/min. Between the binding
cycles, the chip surface was regenerated by the injection of 1 M NaCl for 30 s at a flow of 30 µL/min.
BIAevaluation 4.1.1 software (GE Healthcare) was used to determine binding parameters obtained
based on a global fit with a simple Langmuir model (1:1), with a baseline drift and Rmax locally.
4.12. Mapping of the Fungal Enolase Fragments Involved in the Interactions with VTR, FN and HPG by
Chemical Cross-Linking
4.12.1. Chemical Cross-Linking
VTR, FN or HPG (20 µg in 100 µL PBS, pH 7.4) proteins were incubated in the dark at 4 ◦C for 2
h with 0.5 mM sulfo-SDAD (Thermo Fisher Scientific). After stopping the reaction with 50 mM Tris
for 15 min, the excess reagent was removed by dialysis against PBS at 4 ◦C overnight in the dark.
The tested human proteins were incubated with enolase (20 µg in 100 µL PBS, pH 7.4) at 37 ◦C for 1 h
in the dark with gentle shaking. The samples were then placed on ice and exposed to UV radiation
(365 nm) for 15 min (6W, Vilber Lourmat). Covalently linked pairs of human protein–enolase were
dialyzed overnight against 25 mM ammonium bicarbonate buffer (NH4HCO3) at 4 ◦C. The protein
complexes were then reduced with 50 mM dithiothreitol at 60 ◦C for 60 min and alkylated with 55 mM
iodoacetamide at room temperature for 45 min in the dark. Next, 2 µL of trypsin solution (10 ng/µL in
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25 mM NH4HCO3, pH 8.0) were added for 3 h, followed by additional 2 µL of trypsin solution for
an overnight incubation at 37 ◦C. After stopping the reaction with 2 M HCl for 5 min, samples were
centrifuged (15 min, 12,000 rpm), dried in a Speed-Vac (Martin Christ, Osterode am Harz, Germany)
and frozen at −20 ◦C until further use. Occasionally, endoproteinase Glu-C was used for the digestion
instead of trypsin. Analogous experiments were carried out in a reverse order, where first enolase was
linked with sulfo-SDAD and then allowed to interact with human VTR or HPG proteins.
4.12.2. Mass Spectrometric Analysis
After resuspending in 10% acetonitrile with 0.1% formic acid, the peptides were analyzed with
a HCTUltra ETDII ion-trap mass spectrometer equipped with an electrospray ionization ion source
(Bruker, Bremen, Germany) and coupled to an ultra-high-performance liquid chromatograph Dionex
Ultimate 3000 system (Thermo Fisher Scientific). All peptides were separated on a 100 mm × 2.1 mm
Aeris 3.6µm PEPTIDE XB C18 column (Phenomenex, Torrance, CA, USA), with a gradient of 10–60%
of 0.1% formic acid in 80% acetonitrile, at a flow rate of 0.2 µL/min. Mascot Generic format (.mgf) files
were generated by pre-processing the raw data with Data Analysis 4.0 software (Bruker). The obtained
results were analyzed using the Mass Matrix PC server Version 4.3, as previously described [101].
The data set was then searched using Mass Matrix against the Swiss Prot human databases and
NCBI or Swiss Prot fungal database with the following searching parameters: enzyme, —trypsin or
endoproteinase Glu-C; missed cleavage, 3; peptide length, 4 to 50 amino acid residues; mass tolerances,
−0.6 Da; fragmentation, —CID (collision-induced dissociation); and score thresholds of 4 for the pp
(statistical scores evaluating a peptide match based on the number of matched product ions in the
experimental spectrum), pp2 (statistical scores based on the total abundance of matched product ions
in the experimental spectrum) and 1.3 for pptag (a statistical score that evaluates the match based on
its color tags) scores. The chemical formula of the sulfo-SDAD between protein and sulfur is specified
as C7OSNH10 with a monoisotopic mass of 156.048 Da in Mass Matrix. The windows version of the
program is available at http://www.massmatrix.net/download/.
4.13. Competition between Human VTR and HPG for the Binding to C. albicans Enolase
This competition assay was again performed in MaxiSorp 96-well microtiter plates (Nunc, Roskilde,
Denmark) where VTR was immobilized by overnight incubation at 4 ◦C (3 pmol protein per well).
The unoccupied surface in each well was blocked with 0.5% BSA in PBS at 37 ◦C for 3 h. After each
step, the wells were washed three times with 1% BSA in PBS. Solutions of 40 nM biotinylated enolase
(25 µL) and 400 nM HPG (25 µL) in PBS were added to the wells together and the plate was incubated
for 1.5 h at 37 ◦C with gentle mixing. After washing out the unbound proteins, the amount of bound
biotinylated enolase was determined using the SA-HRP/TMB detection system. The 100% relative
binding of enolase reference was generated using wells in which the human protein (25 µL) was
replaced with PBS (25 µL). In addition, a second variation of the experiment was also performed,
in which magnesium ions (Mg2+) at a concentration of 5 mM were used at each stage.
4.14. Alignment of the Amino-Acid Sequences of C. albicans, C. tropicalis, and S. cerevisiae Enolases
Fungal enolase sequences were aligned and analyzed using Clustal Omega (1.2.4) [102]. C. albicans
enolase (accession number P30575), C. tropicalis enolase (accession number C5MD83) and S. cerevisiae
enolase (accession number P00929) were selected for these comparisons.
4.15. Model of the Interaction between C. albicans Enolase and HPG, VTR and FN
Homology modelling of C. albicans enolase (uniport ID: P30575) was carried out with the Modeller
package v9.14 [103] using the crystal structure of S. cerevisiae enzyme (PDB ID: 1EBH [58]; the Research
Collaboratory for Structural Bioinformatics Protein Data Bank, http://rcsb.org) as a template (Figure S2
in the Supplementary Material). The VTR structure (uniport ID: P04004, Vitronectin V65 subunit) was
obtained by means of knowledge-based homology modelling method using multiple templates (PDB ID:
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3C7X, 1OC0, 2JQ8 and 3BT1 [61–64]) in Prime software (Schrödinger Release 2019-1, Schrödinger LLC,
New York, NY) (Figure S3 in the Supplementary Material). Lowest energy model with loop refinement
was generated as the output and was used for subsequent analysis. Crystal structure of FN fragment
(aa 297–604) and full-length HPG were taken from the PDB database (ID: 3M7P and 4DUU for FN and
HPG, respectively [59,60]). Protein Preparation Wizard (Schrödinger, LLC) was used to prepare the
final structure of proteins.
The model of interaction was elaborated using an on-line version of the protein-protein docking
software ClusPro 2.0 (Boston University, https://cluspro.bu.edu). In the program, rigid structures
were docked, and next from the group of 1000 structures with the lowest energy based on root
mean-square deviation (RMSD) steric collisions were removed by energy minimization [104,105].
Finally, the resulting protein complexes were analyzed in the PyMOL Molecular Graphics System
(Version 1.7.2.1; Schrödinger LLC) by comparing the distance between the experimentally selected
amino acid residues of both proteins.
5. Conclusions
A certain amount of enolase—a cytosolic enzyme involved in evolutionally conserved metabolic
pathways—appears at the cell surface of the pathogenic yeasts C. albicans and C. tropicalis, where it
moonlights by contributing to pathogen adhesion to human host tissues, and to the activation of
fibrinolysis and ECM degradation. In our present study, the positive interactions of enolase with the
human proteins VTR, FN and HPG, that underlie these pathogenicity-related moonlighting functions
of candidal enolase, were characterized in structural terms.
The quantitative binding parameters determined by SPR method for the interactions of human host
proteins with candidal enolase classified these interactions as relatively tight. The binding strengths
were found to be comparable between human ligands, between cytosolic and cell surface-exposed
C. albicans enolases, and between enolases from two Candida species. In contrast, the binding of VTR,
FN and HPG by the S. cerevisiae enzyme was much weaker.
The chemical cross-linking method was used to map the sites on enolase molecules that come into
direct contact with human proteins. A long sequence 235DKAGYKGKVGIAMDVASSEFYKDGK259
present in C. albicans enolase was suggested to contribute to the binding of all three human proteins
studied. Models for these interactions were developed and indicated the sites on the enolase molecule
for binding of human proteins. These sites were extensively overlapping for these ligands and
well-separated from the catalytic activity center of enolase.
Our present analyses suggest that the cell surface-exposed forms of C. albicans and C. tropicalis
enolases may play an important role in the adhesion to host proteins, whilst the cytosolic forms retain
their basic intracellular enzymatic function in central metabolism. This dual role may be a form of
adaptation of previously unused molecular fragments as new binding sites. Thus, internal enolase
motifs identified as points of pathogenicity-related interactions with host proteinaceous ligands may
be promising targets for future drug design.
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Abbreviations
ECM extracellular matrix
FN fibronectin
FN-Bt biotin-labeled fibronectin
HPG human plasminogen
HPG-Bt biotin-labeled human plasminogen
LC-MS/MS liquid chromatography-coupled tandem mass spectrometry
R-Eno recombinant enolase of C. albicans
R-Enosc recombinant enolase of C. albicans with a sequence of S. cerevisiae
SA-HRP/TMB streptavidin-horseradish peroxidase/tetramethylbenzidine
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis
sulfo-SDAD sulfosuccinimidyl 2-([4,4′-azipentanamido]ethyl)-1,3′-dithiopropionate
SPR surface plasmon resonance
VTR vitronectin
VTR-Bt biotin-labeled vitronectin
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